María Luisa Alés-Palmer

Dr. María Luisa Alés-Palmer

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
FAFrancisco Andujar-Vera
Francisco Andujar-Vera
MAMaría Luisa Alés-Palmer
María Luisa Alés-Palmer
PMPaloma Muñoz-De-Rueda
Paloma Muñoz-De-Rueda
IIIvan Iglesias-Baena
Ivan Iglesias-Baena
EOEsther Ocete-Hita
Esther Ocete-Hita
Hepatotoxicity, a common adverse drug effect, has been extensively studied in adult patients. However, it is equally important to investigate this condition in pediatric patients to develop personalized treatment strategies for children. This study aimed to identify plasma biomarkers that characterize hepatotoxicity in pediatric patients through an observational case–control study. Metabolomic analysis was conducted on 55 pediatric patients with xenobiotic liver toxicity and 88 healthy controls. The results revealed clear differences between the two groups. Several metabolites, including hydroxydecanoylcarnitine, octanoylcarnitine, lysophosphatidylcholine, glycocholic acid, and taurocholic acid, were identified as potential biomarkers (area under the curve: 0.817; 95% confidence interval: 0.696–0.913). Pathway analysis indicated involvement of primary bile acid biosynthesis and the metabolism of taurine and hypotaurine (p < 0.05). The findings from untargeted metabolomic analysis demonstrated an increase in bile acids in children with hepatotoxicity. The accumulation of cytotoxic bile acids should be further investigated to elucidate the role of these metabolites in drug-induced liver injury.

1 June 2019 in Minerva Pediatrics
Verified
Journal Article
Closed access
EUEmilia Urrutia-Maldonado
Emilia Urrutia-Maldonado
MAMaría Luisa Alés-Palmer
María Luisa Alés-Palmer
PRPaloma Muñoz De Rueda
Paloma Muñoz De Rueda
IPIrene Peláez-Pleguezuelos
Irene Peláez-Pleguezuelos
EOEsther Ocete-Hita
Esther Ocete-Hita
The molecular interactions between killer-cell immunoglobulin-like receptors (KIRs) and their related HLA class I ligands play a central role in regulating the responses of natural killer (NK) cells. Our study aim was to determine the role played by KIR genes and their HLA ligands in the genetic predisposition for the development of hepatotoxicity in children treated with chemotherapy for an oncological process. The study group was composed of 22 children with cancer, being treated with chemotherapy at the Unit of Pediatric Oncology of the Maternity Hospital Virgen de las Nieves (Granada, Spain) and presenting signs of drug-induced liver injury (DILI). Twenty-four children receiving similar treatment but presenting no signs of DILI were selected as a control group. The children with the KIR K2DS2 were four times more likely to have hepatotoxicity (OR=4.08, P=0.034, 95% CI: 1.1-15). The patients with 2DS2 and the C1 ligand were ten times more likely to undergo an episode of hepatotoxicity (P=0.007). KIRs may be risk factors for susceptibility to hepatotoxicity following chemotherapy.

11 June 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
MAMaría Luisa Alés-Palmer
María Luisa Alés-Palmer
FAFrancisco Andujar-Vera
Francisco Andujar-Vera
IIIvan Iglesias-Baena
Ivan Iglesias-Baena
PMPaloma Muñoz-De-Rueda
Paloma Muñoz-De-Rueda
EOEsther Ocete-Hita
Esther Ocete-Hita
Idiosyncratic drug-induced liver injury (DILI) is a complex multifactorial disease in which the toxic potential of the drug, together with genetic and acquired factors and deficiencies in adaptive processes, which limit the extent of damage, may determine susceptibility and make individuals unique in their development of hepatotoxicity. In our study, we sequenced the exomes of 43 pediatric patients diagnosed with DILI to identify important gene variations associated with this pathology. The result showed the presence of two variations in the NAT2 gene: c.590G>A (p.Arg197Gln) and c.341T>C (p.Ile114Thr). These variations could be found separately or together in 41 of the 43 patients studied. The presence of these variations as a risk factor for DILI could confirm the importance of the acetylation pathway in drug metabolism.